The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
Authors Wang M, Wu S, Tong A, Cui X, Ma X
Received 12 June 2019
Accepted for publication 1 August 2019
Published 22 August 2019 Volume 2019:11 Pages 7981—7989
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Manni Wang, Shuang Wu, An Tong, Xiwei Cui, Xuelei Ma
Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, People’s Republic of China
Correspondence: Xuelei Ma
Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, No. 37, Guoxue Alley, Chengdu 610041, People’s Republic of China
Background: Recent studies have suggested a significant relationship between inflammatory indexes such as the neutrophil-to-lymphocyte ratio (NLR) and survival outcomes in various cancers. The aim of the present study was to evaluate the prognostic value of 6 pretreatment inflammatory markers in patients with primary angiosarcoma (AS) which is a rare and highly malignant type of soft tissue sarcoma.
Methods: Fifty-six patients diagnosed with primary AS at West China Hospital between August 2009 and July 2016 were retrospectively enrolled. The value of each biomarker was calculated for its correlation with patients’ overall survival.
Results: The low tumor grade, tumor size <5 cm, metastatic status, surgical treatment and low level of monocyte-to-lymphocyte ratio, NLR and lactate dehydrogenase (LDH) were correlated with better survival outcome in univariate analyses. In multivariate analyses, high levels of NLR (HR 2.673, 95% CI 1.253–5.703, p=0.011) and LDH (HR 2.964, 95% CI 1.464–5.998, p=0.003) were selected as independent prognostic factors.
Conclusion: This study identifies the elevated pretreatment levels of NLR and LDH as prognostic markers in patients with primary AS.
Keywords: inflammatory biomarker, prognosis, angiosarcoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]